Christopher R. Chapple
Royal Hallamshire Hospital
Sheffield
UK
Name/email consistency: high
- Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder. Chapple, C.R., Kaplan, S.A., Mitcheson, D., Klecka, J., Cummings, J., Drogendijk, T., Dorrepaal, C., Martin, N. Eur. Urol. (2013)
- Silodosin : a new subtype selective alpha-1 antagonist for the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia. Osman, N.I., Chapple, C.R., Cruz, F., Desgrandchamps, F., Llorente, C., Montorsi, F. Expert. Opin. Pharmacother (2012)
- Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Chapple, C.R., Montorsi, F., Tammela, T.L., Wirth, M., Koldewijn, E., Fernández Fernández, E. Eur. Urol. (2011)
- New once-daily formulation for trospium in overactive bladder. Chapple, C. Int. J. Clin. Pract. (2010)
- Antimuscarinics in men with lower urinary tract symptoms suggestive of bladder outlet obstruction due to benign prostatic hyperplasia. Chapple, C. Curr. Opin. Urol (2010)
- Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Chapple, C., Herschorn, S., Abrams, P., Sun, F., Brodsky, M., Guan, Z. Eur. Urol. (2009)
- Management of the failure of a permanently implanted urethral stent-a therapeutic challenge. Chapple, C.R., Bhargava, S. Eur. Urol. (2008)
- Comparison of fesoterodine and tolterodine in patients with overactive bladder. Chapple, C.R., Van Kerrebroeck, P.E., Jünemann, K.P., Wang, J.T., Brodsky, M. BJU Int. (2008)
- The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Chapple, C.R., Khullar, V., Gabriel, Z., Muston, D., Bitoun, C.E., Weinstein, D. Eur. Urol. (2008)
- Darifenacin treatment of patients >or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial. Chapple, C., DuBeau, C., Ebinger, U., Rekeda, L., Viegas, A. Curr. Med. Res. Opin (2007)
- Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Chapple, C., Van Kerrebroeck, P., Tubaro, A., Haag-Molkenteller, C., Forst, H.T., Massow, U., Wang, J., Brodsky, M. Eur. Urol. (2007)
- A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Chapple, C.R., Roehrborn, C.G. Eur. Urol. (2006)
- The urgency of the problem and the problem of urgency in the overactive bladder. Chapple, C.R., Wein, A.J. BJU Int. (2005)
- A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. Chapple, C., Steers, W., Norton, P., Millard, R., Kralidis, G., Glavind, K., Abrams, P. BJU Int. (2005)
- Primer: questionnaires versus urodynamics in the evaluation of lower urinary tract dysfunction-one, both or none?. Chapple, C.R. Nature Clinical Practice. Urology (2005)
- Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. Chapple, C.R., Araño, P., Bosch, J.L., De Ridder, D., Kramer, A.E., Ridder, A.M. BJU Int. (2004)
- Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. Chapple, C.R., Rechberger, T., Al-Shukri, S., Meffan, P., Everaert, K., Huang, M., Ridder, A. BJU Int. (2004)
- Consensus statement on urethral trauma. Chapple, C., Barbagli, G., Jordan, G., Mundy, A.R., Rodrigues-Netto, N., Pansadoro, V., McAninch, J.W. BJU Int. (2004)
- Darifenacin: a novel M3 muscarinic selective receptor antagonist for the treatment of overactive bladder. Chapple, C.R. Expert. Opin. Investig. Drugs (2004)
- Urology. Introduction. Chapple, C.R. Urology (2003)
- Tolterodine: selectivity for the urinary bladder over the eye (as measured by visual accommodation) in healthy volunteers. Chapple, C.R., Nilvebrant, L. Drugs. R. D (2002)
- Tamsulosin: an overview. Chapple, C., Andersson, K.E. World. J. Urol (2002)
- Randomized controlled trials for benign prostatic obstruction: problems and pitfalls. Chapple, C.R. BJU Int. (2000)
- Urethral injury. Chapple, C.R. BJU Int. (2000)
- Contemporary management of urethral trauma and the post-traumatic stricture. Chapple, C.R., Png, D. Curr. Opin. Urol (1999)
- Transurethral needle ablation (TUNA). A critical review of radiofrequency thermal therapy in the management of benign prostatic hyperplasia. Chapple, C.R., Issa, M.M., Woo, H. Eur. Urol. (1999)
